Riskpilot← Back to searchSign inGet full accessCINDA PHARMA AB
ABActiveOrg 5590887906Arvid Wallgrens Backe 20Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2024
SEK 0
EBITDA margin
—
+98% vs 2023
Equity ratio
78.3%
Financial strength
Net profit 2024
SEK -50K
+98% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -50K | +98% |
| Net profit | SEK -50K | +98% |
| Total assets | SEK 60K | -46% |
| Equity | SEK 47K | -8% |
| Employees | 0 | — |
Legal name
CINDA PHARMA AB
Org number
5590887906
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 december 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva forskning och utveckling av läkemedel samt därmed förenlig verksamhet.
Address
Arvid Wallgrens Backe 20
Email
mats.jonasson@obliquet.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −8 | — | −33 919 | −16 574 | −15 302 | −12 193 | −4 735 | −2 144 | −50 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −50 | −200 | −150 | −0 |
| EBIT | −8 | 0 | −33 919 | −16 574 | −15 302 | −12 243 | −4 935 | −2 294 | −50 |
| Net financials | — | — | — | −31 | −634 | −17 | — | — | — |
| Profit before tax | −8 | 0 | −33 919 | −16 605 | −15 936 | −12 260 | −4 935 | −2 294 | −50 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −8 | 0 | −33 919 | −16 605 | −15 936 | −12 260 | −4 935 | −2 294 | −50 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 051 | 21 160 | 2 447 | 2 053 | 2 011 | 1 960 | 1 761 | 111 | 60 |
| Equity | 42 | 42 | 52 | 52 | 53 | 51 | 52 | 51 | 47 |
| Long-term debt | 0 | 2 000 | 2 000 | 2 000 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 009 | 19 118 | 395 | 1 | 1 957 | 1 909 | 1 710 | 60 | 13 |
| Total debt | 2 009 | 21 118 | 2 395 | 2 001 | 1 957 | 1 909 | 1 710 | 60 | 13 |
EBITDA margin
-5000000.0%
This company
15.8%
Market median
-31645670% vs market
20162024
Equity ratio
78.3%
This company
38.2%
Market median
+105% vs market
20162024
Return on equity
-106.4%
This company
18.4%
Market median
-678% vs market
20162024
Net profit margin
-5000000.0%
This company
8.1%
Market median
-61728495% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-12-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JO Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
JD Chief Auditor | Chief Auditor | 2020 | — | — |
UG Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Oblique Therapeutics Ab (Publ) | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oblique Therapeutics Ab (Publ)
CINDA PHARMA AB Board members of CINDA PHARMA AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Christer Emanuel Nordstedt | Chief Executive Officer | 0 companies |
| Jan Owe Owesson Orwar | Chief Executive Officer | 0 companies |
| Johan Daniel Haglund | Chief Auditor | 0 companies |
| Ulf Greger Johansson Längvik | Chief Auditor | 0 companies |
| Ann-Charlotte Sörensson Ostler | Deputy Board Member | 0 companies |
| Linnéa Carolina Trkulja | Chairman | 0 companies |
| Mats Reiner Jonasson | Deputy Board Member | 0 companies |
| Daniel Johnsson | Chairman | 0 companies |
| Hans-Peter Albert Ostler | Board of Directors | 0 companies |